First-line pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction adenocarcinoma: Health-related quality of life from the randomized phase III KEYNOTE-859 trial

作者：Maeve A. Lowery, Lucjan Wyrwicz, Do‐Youn Oh, Kai‐Keen Shiu, Patricio Yañez, Yuxian Bai, Min‐Hee Ryu, Jeeyun Lee, Fernando Rivera, Gustavo Vasconcelos Alves, Marcelo Garrido, Manuel González Fernández, Jin Li, Timuçin Çil, Felipe José Silva Melo Cruz, Shukui Qin, Yanfen Guan, Adriana Valderrama, Sonal Bordia, Sun Young Rha · 发表于：European Journal of Cancer · 年份：2025 · DOI：10.1016/j.ejca.2025.115807 · 被引用次数：2 · 研究领域：Gastric Cancer Management and Outcomes、Cancer Immunotherapy and Biomarkers、HER2/EGFR in Cancer Research